amount of 177Lu for every cycle? Although this is now the standard approach, it is reasonable to ask whether advantages might accrue to administering different amounts of radioactivity at different treatment cycles. Kulkarni et al. from the Zentralklinik Bad Berka (Germany) reported on “Serial dosimetry during 177Lu-PSMA radioligand therapy in the same patient” [316]. The authors performed dosi...

As an alternative to classical brachytherapy, intratumoral injection of radionuclide-labeled nanoparticles (nanobrachytherapy, NBT) has been investigated as a superior delivery method over intravenous route for radionuclide therapy solid tumors. We created superparamagnetic iron oxide (SPIONs) coated with meso-1,2-dimercaptosuccinic acid (DMSA) and radiolabeled Lutetium-177 (177Lu), generating ...

Neuroendocrine tumors (NETs) are a heterogeneous family of neoplasms increasing incidence and high prevalence due to their relatively indolent nature. Their wide anatomic distribution characteristic ability secrete hormonally active substances pose unique challenges for clinical management. They also characterized by the common expression somatostatin receptors, target that has been extremely u...

Bone metastases, often a consequence of breast, prostate, and lung carcinomas, are characterized by an increased bone turnover, which can be visualized by positron emission tomography (PET), as well as single-photon emission computed tomography (SPECT). Bisphosphonate complexes of 99mTc are predominantly used as SPECT tracers. In contrast to SPECT, PET offers a higher spatial resolution and, ow...

Peptide receptor radionuclide therapy (PRRT) with [177Lu-DOTA0,Tyr3]octreotate (177Lu-DOTATATE) is a treatment with good results in patients with metastatic gastroenteropancreatic neuroendocrine tumours (GEPNETs). However, there are some pitfalls that should be taken into consideration when evaluating the treatment response after PRRT. 354 Dutch patients with GEPNETs who were treated with 177Lu...

introduction: the aim of the present study was to evaluate the efficacy and safety profile of bone palliative therapy following administration of 153sm-edtmp in patients with intractable metastatic bone pain. methods: sixteen patients (9 male, 7 female) aged 29-80 years (57.3±16.7 years) with severe metastasis-related bone pain resistant to analgesic medications were enrolled in the study. all...

Fifteen dogs were referred because of a spontaneous bone tumor, lameness, and local pain. The osteosarcoma diagnosis was established by clinical examination, X-ray, bone scintigraphy, and histological examination of biopsy material. The tumors were located in the extremities (n = 12), scapula (n = 1), maxilla (n = 1), and the frontal bone (n = 1). The dogs were given one to four i.v. injections...

Introduction This work presents a comparative biological evaluation of 90Y- and 177Lu- labelled DOTA-SCN and DOTA-NHS conjugated to Rituximab in tumour-bearing mice. Materials and methods Two DOTA derivatives, p-SCN-Bn-DOTA and DOTA-NHS-ester were conjugated to Rituximab and then freeze-dried kit formulations were prepared, as previously described [1]. Tissue distribution was investigated in t...

Introduction This work presents a comparative biological evaluation of 90Y- and 177Lu- labelled DOTA-SCN and DOTA-NHS conjugated to Rituximab in tumour-bearing mice. Materials and methods Two DOTA derivatives, p-SCN-Bn-DOTA and DOTA-NHS-ester were conjugated to Rituximab and then freeze-dried kit formulations were prepared, as previously described [1]. Tissue distribution was investigated in t...